Status:
COMPLETED
Changes of Transforming Growth Factor b1 and Procollagen III in Patients With Acute Respiratory Distress Syndrome
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Acute Respiratory Distress Syndrome
Eligibility:
All Genders
18-90 years
Brief Summary
Transforming Growth Factor-b1 (TGF-b1) is involved in the development of acute lung injury and in the fibroproliferation during acute respiratory distress syndrome (ARDS). Procollagen III Peptide (PII...
Detailed Description
Primary outcome: To analyse the changes of Transforming Growth Factor b1 and Procollagen III during the acute respiratory distress syndrome.
Eligibility Criteria
Inclusion
- ARDS with a PaO2/FIO2 \< 200 mmHg at a positive end-expiratory pressure (PEEP) ³ 5 cm H2O
- ARDS criteria from less than 24 hours
- Informed consent
Exclusion
- Pregnancy
- Chronic interstitial or fibrosis lung diseases
- Hepatic chronic disease
- Neutropenia £1 G/l
- Corticosteroid (more than 200 mg/day of hydrocortisone or equivalent, less than 2 weeks before inclusion)
- Immunosuppressive therapy within the last 30 days
- Participation in any investigational drug or devices study within 30 days prior study entry
Key Trial Info
Start Date :
September 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00440882
Start Date
September 1 2004
Last Update
October 9 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Sainte Marguerite
Marseille, France, 13009